Product Description
Mechanisms of Action: GABA Agonist,NF-KB Inhibitor,CAAP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Bulgaria | Chile | China | Croatia | Egypt | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Japan | Korea | Malaysia | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Russia | Serbia | Spain | Sweden | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|